ما هو علاج الخط الأول لالتهاب القولون المجهري؟

References

DOI: 10.1053/j.gastro.2015.11.008

• Patients treated with 9 mg of budesonide daily were more than twice as likely to achieve clinical remission over an average of 7 to 13 days when compared with no treatment (relative risk, 2.52; 95% confidence interval, 1.45–4.4).
• Because of the highly favorable risk/benefit profile and convenience of once-daily dosing, budesonide should be considered first-line therapy for the treatment of microscopic colitis.
• Cessation of budesonide can be considered after 8 weeks of therapy.